Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
abbvie
7
×
biotech
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
merck
7
×
national
national blog main
national top stories
new york blog main
new york top stories
7
×
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
7
×
seattle top stories
texas blog main
texas top stories
wisconsin blog main
7
×
wisconsin top stories
7
×
startups
alzheimer's disease
bristol-myers squibb
cancer
deals
eli lilly
novartis
pfizer
astrazeneca
cancer immunotherapy
clinical trials
What
bio
roundup
drug
companies
acquisitions
biggest
ceo
debut
moves
nash
news
today
week
albert
approval
approved
away
biogen’s
biopharma
biopharmaceutical
black
bourla
bringing
build
buy
car
celgene
ceos
colleagues
company
company’s
continue
convo
crispr
daniel
dc
diamond
diamond’s
digital
disease
Language
unset
unknown
Current search:
abbvie
×
merck
×
" seattle blog main "
×
" new york top stories "
×
" wisconsin top stories "
×
" wisconsin blog main "
×
@xconomy.com
4 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
5 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Pharma CEOs to Senate: We Will Lower Drug Prices if Rebates Go Away
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More